Search

Objectives: In this study, effect of methylprednisolone on bone mineral density (BMD) was investigated in rats with overiectomy induced bone lose and suppressed endogenous adrenalin levels, and compared to alendronate. Materials and Methods: Severity of bone loss in the examined material (femur bones) was evaluated by BMD measurement. Results: The group with the highest BMD value was metyrosinemetyrosine + methylprednisolone combination (0.151 g/cm 2 ), while that with the lowest BMD was methylprednisolone (0.123 g/cm 2 ). Alendronate was effective only when used alone in ovariectomized rats (0.144 g/cm 2 ), but not when used in combination with methylprednisolone (0.124 g/cm 2 ). In the ovariectomized rat group which received only metyrosine, BMD value was statistically indifferent from ovariectomized control group. Conclusions: Methylprednisolone protected bone loss in rats with suppressed adrenaline levels because of metyrosinemetyrosine.

Metastatic calcification related to renal failure has been well described. There is uptake of bone-scanning agents at extraskeletal sites in metastatic calcification. A 34-year-old man with end-stage renal failure was treated with hemodialysis. He noticed a painful lump over his right shoulder. Anterior and posterior whole-body bone scintigraphy images revealed markedly increased uptake in the heart, right shoulder, and medial part of the left shoulder. A biopsy of the right shoulder area showed metastatic calcium deposition.

OP-048 Percutaneous coronary intervention (PCI) does not often have optimal results despite restoration of coronary blood flow at myocardial recovery because of impaired microvascular perfusion. Previous studies have focused on the starting time and dosage of tirofiban. This study aimed to